| Index | — | P/E | — | EPS (ttm) | -8.41 | Insider Own | 2.69% | Shs Outstand | 58.87M | Perf Week | 20.01% |
| Market Cap | 2.07B | Forward P/E | 8.61 | EPS next Y | 4.08 | Insider Trans | 0.89% | Shs Float | 57.99M | Perf Month | 36.66% |
| Enterprise Value | 3.01B | PEG | — | EPS next Q | 0.68 | Short Float | 9.15% | Perf Quarter | 19.28% | ||
| Income | -496.00M | P/S | 0.45 | EPS this Y | -50.54% | Short Ratio | 6.06 | Perf Half Y | 4.56% | ||
| Sales | 4.57B | P/B | 0.95 | EPS next Y | 97.20% | ROA | -4.15% | Short Interest | 5.31M | Perf YTD | -13.47% |
| Book/sh | 36.98 | P/C | 3.74 | EPS next 5Y | 58.57% | ROE | -19.33% | 52W High | 45.08 -24.77% | Perf Year | -22.03% |
| Cash/sh | 0.00 | P/FCF | 4.36 | EPS past 3/5Y | — -17.90% | ROIC | -4.23% | 52W Low | 22.69 49.47% | Perf 3Y | -17.44% |
| Dividend Est. | 1.28 (3.77%) | EV/EBITDA | — | Sales past 3/5Y | -4.14% -1.50% | Gross Margin | 36.16% | Volatility | 5.31% 3.85% | Perf 5Y | -48.87% |
| Dividend TTM | 1.28 (3.77%) | EV/Sales | 0.66 | EPS Y/Y TTM | -258.36% | Oper. Margin | -11.40% | ATR (14) | 1.28 | Perf 10Y | -6.20% |
| Dividend Ex-Date | Aug 21, 2026 | Quick Ratio | — | Sales Y/Y TTM | -4.11% | Profit Margin | -10.83% | RSI (14) | 79.48 | Recom | 2.75 |
| Dividend Gr. 3/5Y | 1.06% 1.30% | Current Ratio | — | EPS Q/Q | -65.38% | SMA20 | 20.20% | Beta | 1.02 | Target Price | 35.50 |
| Payout | — | Debt/Eq | 0.43 | Sales Q/Q | -10.99% | SMA50 | 26.09% | Rel Volume | 0.99 | Prev Close | 35.08 |
| Employees | 7,350 | LT Debt/Eq | 0.43 | Earnings | Nov 09 | SMA200 | 18.16% | Avg Volume | 884.70K | Price | 33.91 |
| IPO Date | Apr 23, 1990 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 31.85% -6.18% | Net Debt/EBITDA | — | Volume | 878,944 | Change | -3.32% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Aug-10-26 | Reiterated | UBS | Buy | $44 → $43 |
| May-11-26 | Reiterated | UBS | Buy | $48 → $44 |
| May-07-26 | Reiterated | Piper Sandler | Underweight | $80 → $28 |
| Apr-08-26 | Reiterated | UBS | Buy | $56 → $48 |
| Feb-09-26 | Reiterated | UBS | Buy | $65 → $56 |
| Feb-05-26 | Downgrade | Citizens | Market Outperform → Market Perform | |
| Dec-18-25 | Downgrade | William Blair | Market Perform → Underperform | |
| Aug-07-25 | Downgrade | Raymond James | Strong Buy → Outperform | $75 → $60 |
| Aug-06-25 | Downgrade | Piper Sandler | Overweight → Underweight | |
| Aug-08-24 | Reiterated | Raymond James | Strong Buy | $128 → $75 |
Kemper Corporation functions as a comprehensive insurance holding entity, providing a wide array of property and casualty, alongside life and health insurance coverage throughout the United States. Its operations are divided into three primary segments: Specialty Property & Casualty Insurance, Preferred Property & Casualty Insurance, and Life & Health Insurance. The company offers individual clients a variety of property and casualty protection, such as automobile, homeowners', renters', fire, umbrella, and general liability policies. Additionally, it supplies commercial automobile insurance for businesses. Regarding life and health offerings, Kemper delivers diverse life insurance products, including both permanent and term options. It also provides supplementary accident and health plans, Medicare supplemental insurance, fixed hospital indemnity, home health care services, specific disease policies, and accident-only coverage, tailored for individuals across rural, suburban, and urban environments. Its insurance solutions are primarily distributed via a network of independent agents and brokers. Established in 1990 and based in Chicago, Illinois, the company rebranded as Kemper Corporation in August 2011, having previously operated under the name Unitrin, Inc.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 4,574 | 4,801 | 4,633 | 4,945 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 2,920 | 3,376 | 4,043 | 3,820 | — | — | — | — | — | |
| Gross Profit | 1,654 | 1,425 | 589 | 1,125 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 0 | 1,164 | -3 | 0 | — | — | — | — | — | |
| Research and Development | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Other Operating Expense | 2,176 | 100 | 204 | 1,472 | — | — | — | — | — | |
| Operating Income | -521 | 161 | 389 | -347 | — | — | — | — | — | |
| Interest Expense | 36 | 39 | 57 | 56 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 36 | 39 | 57 | 56 | — | — | — | — | — | |
| Net Income Before Taxes | -521 | 161 | 389 | -347 | — | — | — | — | — | |
| Income Taxes | -16 | 28 | 76 | -75 | — | — | — | — | — | |
| Consolidated Net Income | -496 | 143 | 318 | -272 | — | — | — | — | — | |
| Net Income From Continuing Operations | -504 | 133 | 313 | -272 | — | — | — | — | — | |
| Net Income | -496 | 143 | 318 | -272 | — | — | — | — | — | |
| EPS (Recurring) | -8.41 | 2.31 | 4.95 | -4.25 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -8.41 | 2.31 | 4.95 | -4.25 | — | — | — | — | — | |
| EPS (Diluted) | -8.41 | 2.29 | 4.91 | -4.25 | — | — | — | — | — | |
| EBITDA | -440 | 274 | 499 | -232 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | 17.70 | 13.53 | — | — | — | — | — | — | |
| Price To Sales Ratio | 0.44 | 0.52 | 0.92 | 0.63 | — | — | — | — | — | |
| Gross Margin | 36.16 | 29.68 | 12.71 | 22.75 | — | — | — | — | — | |
| Operating Margin | -11.39 | 3.35 | 8.40 | -7.02 | — | — | — | — | — | |
| Net Margin | -10.84 | 2.98 | 6.86 | -5.50 | — | — | — | — | — | |
| Shares Outstanding | 59 | 62 | 64 | 64 | — | — | — | — | — | |
| Market Capitalization | 2,001 | 2,513 | 4,252 | 3,115 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| McAnena Stephen J | President and CEO | Aug 13 '26 | Buy | 26.50 | 3,000 | 79,500 | 30,945 | Aug 13 |
| Camden Bradley T | EVP and CFO | Aug 11 '26 | Buy | 26.34 | 1,000 | 26,340 | 51,259 | Aug 11 |
| Evans Carl Thomas Jr. | EVP, Sec. & General Counsel | Aug 11 '26 | Buy | 26.53 | 1,000 | 26,530 | 91,629 | Aug 11 |
| LADERMAN GERALD | Director | Aug 11 '26 | Buy | 26.49 | 4,000 | 105,960 | 33,365 | Aug 11 |
| Gorevic Jason N | Director | Aug 10 '26 | Buy | 25.91 | 5,000 | 129,550 | 31,802 | Aug 11 |
| MCKINNEY SUZET M | Director | Feb 06 '26 | Sale | 34.66 | 504 | 17,469 | 5,060 | Feb 09 |
| Parker Stuart B. | Director | Nov 10 '25 | Buy | 36.82 | 25,000 | 920,500 | 48,152 | Nov 12 |
| LACHER JOSEPH P JR | President and CEO | Sep 10 '25 | Option Exercise | 40.70 | 98,280 | 3,999,996 | 252,953 | Sep 11 |
| LADERMAN GERALD | Director | Aug 07 '25 | Buy | 49.37 | 3,000 | 148,110 | 24,635 | Aug 07 |
| Canida Teresa Alvarez | Director | Aug 07 '25 | Buy | 48.96 | 2,000 | 97,920 | 28,521 | Aug 07 |
| Flint Christopher Wade | EVP, President, Kemper Life | Aug 07 '25 | Buy | 50.12 | 1,000 | 50,115 | 10,197 | Aug 07 |
| Gorevic Jason N | Director | Aug 07 '25 | Buy | 49.14 | 2,000 | 98,280 | 22,072 | Aug 07 |
| Cochran George N | Director | Jun 11 '25 | Option Exercise | 37.71 | 9,179 | 346,185 | 37,330 | Jun 13 |
| Paracchini Alberto J | Director | Jun 10 '25 | Buy | 61.71 | 500 | 30,855 | 10,323 | Jun 11 |
| LADERMAN GERALD | Director | Jun 10 '25 | Buy | 62.24 | 2,500 | 155,600 | 21,635 | Jun 11 |